LACTULOSE FOR ORAL SOLUTION Rx only

Manufacturer
Trifluent Pharma, Inc.
Effective date
2025-09-13
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 21:42:54

Label at a glance#

ProductLactulose
Active ingredientLACTULOSE
Label structure15 sections

Indications and uses

Lactulose for Oral Solution is indicated for the treatment of constipation. In patients with a history of chronic constipation, lactulose therapy increases the number of bowel movements per day and the number of days on which bowel movements occur.

Dosage and administration

The usual adult dosage is 10 g to 20 g of lactulose daily. The dose may be increased to 40 g daily if necessary. Twenty-four to 48 hours may be required to produce a normal bowel movement.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Lactulose for Oral Solution is a synthetic disaccharide in the form of crystals for reconstitution prior to use for oral administration. Each 10 g of lactulose contains less than 0.3 g galactose and lactose as a total sum. The pH range is 3.0 to 7.0.

Lactulose is a colonic acidifier which promotes laxation.

The chemical name for lactulose is 4-O-β-D-Galactopyranosyl-D-fructofuranose. It has the following structural formula:

Lactulose Chemical StructureLactulose Chemical Structure

The molecular formula is C 12H 22O 11. The molecular weight is 342.30. It is freely soluble in water.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Lactulose is poorly absorbed from the gastrointestinal tract and no enzyme capable of hydrolysis of this disaccharide is present in human gastrointestinal tissue. As a result, oral doses of lactulose reach the colon virtually unchanged. In the colon, lactulose is broken down primarily to lactic acid, and also to small amounts of formic and acetic acids, by the action of colonic bacteria, which results in an increase in osmotic pressure and slight acidification of the colonic contents. This in turn causes an increase in stool water content and softens the stool.

Since lactulose does not exert its effect until it reaches the colon, and since transit time through the colon may be slow, 24 to 48 hours may be required to produce desired bowel movement.

Lactulose given orally to man and experimental animals resulted in only small amounts reaching the blood. Urinary excretion has been determined to be 3% or less and is essentially complete within 24 hours.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Lactulose for Oral Solution is indicated for the treatment of constipation. In patients with a history of chronic constipation, lactulose therapy increases the number of bowel movements per day and the number of days on which bowel movements occur.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Since Lactulose for Oral Solution contains galactose (less than 0.3 g/10 g as a total sum with lactose), it is contraindicated in patients who require a low galactose diet.

WARNINGS

WARNINGS SECTION

A theoretical hazard may exist for patients being treated with lactulose who may be required to undergo electrocautery procedures during proctoscopy or colonoscopy. Accumulation of H 2 gas in significant concentration in the presence of an electrical spark may result in an explosive reaction. Although this complication has not been reported with lactulose, patients on lactulose therapy undergoing such procedures should have a thorough bowel cleansing with a non-fermentable solution. Insufflation of CO 2 as an additional safeguard may be pursued but is considered to be a redundant measure.

PRECAUTIONS

PRECAUTIONS SECTION

-

General

GENERAL PRECAUTIONS SECTION

Since Lactulose for Oral Solution contains galactose and lactose (less than 0.3 g/10 g as a total sum), it should be used with caution in diabetics.

Information for Patients

INFORMATION FOR PATIENTS SECTION

In the event that an unusual diarrheal condition occurs, contact your physician.

Laboratory Tests

LABORATORY TESTS SECTION

Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically.

Drug Interactions

DRUG INTERACTIONS SECTION

Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH. Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

There are no known human data on long-term potential for carcinogenicity, mutagenicity, or impairment of fertility.

There are no known animal data on long-term potential for mutagenicity.

Administration of lactulose syrup in the diet of mice for 18 months in concentrations of 3 and 10 percent (v/w) did not produce any evidence of carcinogenicity.

In studies in mice, rats, and rabbits, doses of lactulose syrup up to 6 or 12 mL/kg/day produced no deleterious effects in breeding, conception, or parturition.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects

Reproduction studies have been performed in mice, rats, and rabbits at doses up to 3 or 6 times the usual human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to lactulose. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when lactulose is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Precise frequency data are not available.

Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia, and hypernatremia.

Nausea and vomiting have been reported.

OVERDOSAGE

OVERDOSAGE SECTION

-

Signs and Symptoms

SPL UNCLASSIFIED SECTION

There have been no reports of accidental overdosage. In the event of overdosage, it is expected that diarrhea and abdominal cramps would be the major symptoms. Medication should be terminated.

Oral LD 50

SPL UNCLASSIFIED SECTION

The acute oral LD 50of the drug is 48.8 mL/kg in mice and greater than 30 mL/kg in rats.

Dialysis

SPL UNCLASSIFIED SECTION

Dialysis data are not available for lactulose. Its molecular similarity to sucrose, however, would suggest that it should be dialyzable.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The usual adult dosage is 10 g to 20 g of lactulose daily. The dose may be increased to 40 g daily if necessary. Twenty-four to 48 hours may be required to produce a normal bowel movement.

DIRECTIONS FOR PREPARATION

SPL UNCLASSIFIED SECTION

Dissolve contents of packet in half a glass (4 ounces) of water.

When Lactulose for Oral Solution is dissolved in water, the resulting solution may be colorless to a slightly pale yellow color.

HOW SUPPLIED

HOW SUPPLIED SECTION

Lactulose for Oral Solution is available in single dose packets of 10 g (NDC 73352-900-01) and single dose packets of 20 g (NDC 73352-905-01). The packets are supplied as follows:

-

NDC 73352-900-15
(Carton of fifteen 10 g packets)

-

NDC 73352-905-15
(Carton of fifteen 20 g packets)

-

STORE AT ROOM TEMPERATURE, 15°-30°C (59°-86°F).

To report SUSPECTED ADVERSE REACTIONS, contact Trifluent Pharma at 1-888-927-5191 or FDA at 1-800-FDA-1088 orwww.fda.gov/medwatch

-

Distributed by:

Trifluent Pharma, LLC

San Antonio Tx, 78213

IN791631

Rev. 01 04/2025

PRINCIPAL DISPLAY PANEL - 10 g PACKET

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 73352-900-01

Lactulose for Oral Solution

10 Grams

Single Dose Packet

Rx only

CONTENTS:Each packet contains 10 grams of lactulose (and less than 0.3 g galactose and lactose as a total sum).

This unit dose packet is not child resistant.

INDICATIONS:For the treatment of constipation. See accompanying package insert.

USUAL ADULT DOSAGE:10 to 20 grams daily. See accompanying package insert.

Since lactulose does not exert its effect until it reaches the colon, and since transit time through the colon may be slow, 24-48 hours may be required to produce a normal bowl movement.

DIRECTIONS FOR PREPARATION:Dissolve contents of packet in half a glass (4 ounces) of water.

Store at room temperature, 15°-30°C (59°-86°F).

Distributed by:

Trifluent Pharma, LLC

San Antonio TX 78213

PouchPouch

PRINCIPAL DISPLAY PANEL - 10 g CARTON

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 73352-900-15

Lactulose for Oral Solution

10 Grams

15 Single Dose Packets

Rx only

Carton 10Carton 10

PRINCIPAL DISPLAY PANEL - 20 g PACKET

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 73352-905-01

Lactulose for Oral Solution

20 Grams

Single Dose Packet

Rx only

CONTENTS:Each packet contains 20 grams of lactulose (and less than 0.6 g galactose and lactose as a total sum).

This unit dose packet is not child resistant.

INDICATIONS:For the treatment of constipation. See accompanying package insert.

USUAL ADULT DOSAGE:10 to 20 grams daily. See accompanying package insert.

Since lactulose does not exert its effect until it reaches the colon, and since transit time through the colon may be slow, 24-48 hours may be required to produce a normal bowl movement.

DIRECTIONS FOR PREPARATION:Dissolve contents of packet in half a glass (4 ounces) of water.

Store at room temperature, 15°-30°C (59°-86°F).

Distributed by:

Trifluent Pharma, LLC

San Antonio, TX 78213

Foil 20Foil 20

Lactulose for Oral Solution Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Lactulose for ORal Solution

NDC 73352-900-15

Rx Only

Carton 20Carton 20

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1251190lactulose 10 GM Powder for Oral SolutionPSN1
1251194lactulose 20 GM Powder for Oral SolutionPSN1
1251190lactulose 10000 MG Powder for Oral SolutionSCD1
1251194lactulose 20000 MG Powder for Oral SolutionSCD1
1251190lactulose 10 GM Granules for Oral SolutionSY1
1251190lactulose 10 GM Powder for Oral SolutionSY1
1251194lactulose 20 GM Granules for Oral SolutionSY1
1251194lactulose 20 GM Powder for Oral SolutionSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
LACTULOSE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
13620a32-e3b4-4aad-8280-283dce30ddffProduct name120260105
27883b46-af31-44b0-b4ce-e6b4f6d825a7Product name420250812
c1a80c95-0e51-52a0-75fa-75808f51ded8Product name220150421

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
73352-900-01Lactulose10 g in 1 POUCHPOWDER, FOR SOLUTION101
73352-900-15Lactulose15 in 1 CARTONPOWDER, FOR SOLUTION151
73352-905-01Lactulose20 g in 1 POUCHPOWDER, FOR SOLUTION201
73352-905-15Lactulose15 in 1 CARTONPOWDER, FOR SOLUTION151

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
73352-900-01EA - Each73352-900cb17222a-465d-4265-be53-5d8454c625f412025-10-14
73352-900-15EA - Each73352-900bc21dab0-efee-4fb3-8f8f-5b15e052d44a12025-10-14
73352-905-01EA - Each73352-905b871561d-5d97-4bc3-909a-c9a3e13dfcba12025-10-14
73352-905-15EA - Each73352-90534b0a630-1a4f-4882-b34f-da8ca4bcad7512025-10-14

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 1 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
73352-90073352-900-01, 73352-900-15
73352-90573352-905-01, 73352-905-15

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 2 matching rows.

Name, UNII, Kind table
NameUNIIKind
LACTULOSE9U7D5QH5AEACTIB
LACTULOSE9U7D5QH5AEACTIB

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A217914-001LACTULOSELACTULOSE10GM/PACKETFOR SOLUTION / ORALAA2025-03-14
A217914-002LACTULOSELACTULOSE20GM/PACKETFOR SOLUTION / ORALAA2025-03-14

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 2 matching rows.

Application-product, TE code table
Application-productTE code
A217914-001AA
A217914-002AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A217914-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALAA2025-03-1484e616aacf4f…
2026-09-14 22:38:342026-08A217914-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALAA2025-03-1484e616aacf4f…
2026-08-18 06:07:402026-07A217914-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALAA2025-03-14caaa826d4ba7…
2026-08-18 06:07:402026-07A217914-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALAA2025-03-14caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A217914-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALAA2025-03-14011fe1cb6892…
2026-02-19 14:30 UTC2026-02A217914-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALAA2025-03-14011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A217914-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALAA2025-03-1431067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A217914-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALAA2025-03-1431067a03dcf5…
2025-08-23 18:47 UTC2025-08A217914-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALAA2025-03-146a471c1ec25d…
2025-08-23 18:47 UTC2025-08A217914-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALAA2025-03-146a471c1ec25d…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A217914-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALAA2025-03-14a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A217914-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALAA2025-03-14a50c72e98297…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A217914-001AA184e616aacf4f…
2026-09-14 22:38:342026-08A217914-002AA184e616aacf4f…
2026-08-18 06:07:402026-07A217914-001AA1caaa826d4ba7…
2026-08-18 06:07:402026-07A217914-002AA1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A217914-001AA1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A217914-002AA1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A217914-001AA131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A217914-002AA131067a03dcf5…
2025-08-23 18:47 UTC2025-08A217914-001AA16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A217914-002AA16a471c1ec25d…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A217914-001AA1a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A217914-002AA1a50c72e98297…

Observed Orange Book exclusivity history#

Captured, Edition, Application-product table
CapturedEditionApplication-productExclusivity codeExpirationSource SHA-256
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A217914-001CGT2025-09-1331067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A217914-002CGT2025-09-1331067a03dcf5…
2025-08-23 18:47 UTC2025-08A217914-001CGT2025-09-136a471c1ec25d…
2025-08-23 18:47 UTC2025-08A217914-002CGT2025-09-136a471c1ec25d…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
LactuloseLACTULOSETrifluent Pharma, Inc.3eaf273a-b49d-2595-e063-6394a90a1cf62025-09-13Warnings, Adverse reactionsExact identifier
ndc (package): 73352-905-15
ndc (package): 73352-905-01
ndc (package): 73352-900-01
ndc (package): 73352-900-15
ndc (product): 73352-905
ndc (product): 73352-900
ndc11 (package): 73352090001
ndc11 (package): 73352090515
ndc11 (package): 73352090501
ndc11 (package): 73352090015
spl id: 3eaf2342-fb58-e0a5-e063-6394a90a7271
spl set id: 3eaf273a-b49d-2595-e063-6394a90a1cf6

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.